Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)

NCT00348972 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00348972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00348972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety and Tolerability of Lantus® (Insulin Glargine) in Subjects With Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2002
Completion date
Not reported
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, hyperglycemia